Phase III studies of investigational gantenerumab did not meet their primary endpoints of slowing clinical decline in early Alzheimer’s disease, the Roche Group said. Beta-amyloid removal also was lower than expected with the drug.

Source: Advances in technologies to detect early signs of disease from a blood sample are helping doctors to identify the memory-robbing disorder more accurately and to screen participants more quickly for trials of potential treatments.